Therapeutic Angiogenesis: A Complex Problem Requiring a Sophisticated Approach

Cardiovascular Toxicology

Volumn 3, Issue 3, 2003, Pages 283-297

  Webster, Keith A ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Claudication; FGF; Ischemia; MCP 1; Stem cells; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR; FREE RADICAL; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINE; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROLIFERIN; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; SOMATOMEDIN C; THROMBOSPONDIN; THYROXINE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACIDOSIS; ANGIOGENESIS; CELL HYPOXIA; CELL SURVIVAL; CELL VIABILITY; CORONARY ARTERY DISEASE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; NONHUMAN; OXYGEN TRANSPORT; OXYGENATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; BLOOD VESSELS; CORONARY DISEASE; HUMANS; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; VASCULAR DISEASES;

EID: 0142053973     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:3:3:283     Document Type: Review

References (104)

1. Schainfeld, D.O. and Isner, J.M. (1999). Critical limb ischemia: Nothing to give at the office. Ann. Intern. Med. 130:442-444.
2. Isner, J.M. and Asahara, T. (1999). Angiogenesis and vasculogenesis as therapeutic strategies for postnatal vascularization. J. Clin. Invest. 103:1231-1236.
3. The ICAI Study Group. (1999). Prostanoids for chronic leg ischemia: A randomized, controlled, open-label trial with prostaglandin E1. Ann. Intern. Med. 130:412-421.
4. Valentine, R.J., Myers, S.I., Inman, M.H., Roberts, J.R., and Clagett, G.P. (1996). Late out-come of amputees with premature atherosclerosis. Surgery 119:487-493.
5. Lefer, D.J., and Granger, D.N. (2000). Oxidative stress and cardiac disease. Am. J. Med. 109:315-323.
6. Murphy, A.M., Kogler, H., Georgakopoulos, D., McDonough, J.L., Kass, D.A., Van Eyk, J.E., et al. (2000). Transgenic mouse model of stunned myocardium. Science 287:488-491.
7. Bishopric, N.H., Andreka, P., and Slepak, T. (2001). Molecular mechanisms of apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 1:141-150.
8. Buja, L.M. and Entman, M.L. (1998). Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 98:1355-1357.
9. Majno, G. and Joris, I. (1995). Apoptosis, oncosis, and necrosis: an overview of cell death. Am. J. Pathol. 146:3-15.
10. Reimer, K.A. and Ideker, R.E. (1987). Myocardial ischemia and infarction: anatomic and biochemical substrates for ischemic cell death and ventricular arrhythmias. Hum. Pathol. 18:462-475.
11. Allen, D.G. and Orchard, C.H. (1987). Myocardial contractile function during ischemia and hypoxia. Circ. Res. 60:153-168.
12. Allen, D.G., Lee, J.A., and Smith, G.L. (1989). The consequences of simulated ischaemia on intracellular Ca2+ and tension in isolated ferret ventricular muscle. J. Physiol. 410:297-323.
13. Neely, J.R. and Grotyohann, L.W. (1984). Role of glycolytic products in damage to ischemic myocardium. Circ. Res. 55:816-824.
14. Kubasiak, L.A., Hernandez, O.M., Bishopric, N.H., and Webster, K.A. (2002). Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl. Acad. Sci. USA 99:12825-12830.
15. Hochachka, P.W., Buck, L.T., Doll, C.J., and Land, S.C. (1996). Unifying theory of hypoxia tolerance: Molecular/metabolic defence and rescue mechanisms for surviving oxygen lack. Proc. Natl. Acad. Sci. USA 93:9493-9498.
16. Kajstura, J., Cheng, W., Reiss, K., Clark, W.A., Sonnenblick, E.H., Krajewski, S., et al. (1996). Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74:86-107.
17. Ohno, M., Takemura, G., Ohno, A., Misao, J., Hayakawa, Y., Minatoguchi, S., et al. (1998). "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with in situ nick end-labeling. Circulation 98:1422-1430.
18. Gotto, A.M. Jr. (2002). High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. 144 (6 Suppl):S33-S42.
19. Connolly, D.L., Lip, G.Y., and Chin, B.S. (2002). Antithrombotic strategies in acute coronary syndromes and percutaneous coronary interventions. BMJ 325:1404-1407.
20. Mann, M.J. and Dzau, V.J. (2002). Molecular approaches for the treatment of atherosclerosis. Cardiol. Clin. 20:633-643.
21. Ahmed, A. (2003). American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management Guidelines: Relevance to the Geriatric Practice. J. Am. Geriatr. Soc. 51:123-126.
22. Laugwitz, K.L., Moretti, A., Weig, H.J., Gillitzer, A., Pinkernell, K., Ott, T., et al. (2001). Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum. Gene Ther. 12:2051-2063.
23. Rossig, L., Hoffmann, J., Hugel, B., Mallat, Z., Haase, A., Freyssinet, J.M., Tedgui, A., Aicher, A., et al. (2001). Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 104:2182-2187.
24. Frystyk, J., Ledet, T., Moller, N., Flyvbjerg, A., and Orskov, H. (2002). Cardiovascular disease and insulin-like growth factor I. Circulation 106:893-895.
25. Barakate, M.S., Hemli, J.M., Hughes, C.F., Bannon, P.G., and Horton, M.D. (2003). Coronary artery bypass grafting (CABG) after initially successful percutaneous transluminal coronary angioplasty (PTCA): a review of 17 years experience. Eur. J. Cardiothorac. Surg. 23:179-186.
26. Fattori, R. and Piva, T. (2003). Drug-eluting stents in vascular intervention. Lancet 361:247-249.
27. Isner, J.M. (1999). Manipulating angiogenesis against vascular disease. Hosp. Pract. June 15:69-86.
28. Rivard, A., Silver, M., Chen, D., Kearney, M., Magner, M., Annex, B., et al. (1999). Rescue of diabetes-related impairment of angiogenesis by intramuscular gene transfer with Adeno-VEGF. Am. J. Pathol. 154:355-363.
29. Rivard, A., Fabre, J.E., Silver, M., Chen, D., Murohara, T., Kearney, M., et al. (1999). Age-dependent impairment of angiogenesis. Circulation 99:111-120.
30. Melillo, G., Scoccianti, M., Kovesdi, I., Safi, J., Riccioni, T., and Capogrossi, M.C. (1997). Gene therapy for collateral vessel development. Cardiol. Res. 35:480-489.
31. Lewis, B.S., Flugelman, M.Y., Weisz, A., Keren-Tal, I., and Schaper, W. (1997). Angiogenesis by gene therapy: a new horizon for myocardial revascularization. Cardiol. Res. 35:490-497.
32. Li, C.W., Chen, J.Y., and Hua, T.E. (1998). Precambrian sponges with cellular structures. Science 279:879-882.
33. Webster, K.A. (2000). Therapeutic angiogenesis: a case for targeted, regulated gene delivery. Crit. Rev. Eukaryot. Gene Expr. 10:113-125.
34. Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., and Isner, J.M. (1998). Constituive expression of phVEGF 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123.
35. Losordo, D.W., Vale, P.R., Symes, J.F., Dunnington, C.H., Esakof, D.D., Maysky, M., Ashare, A.B., Lathi, K., and Isner, J.M. (1998). Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804.
36. Khan, T.A., Sellke, F.W., and Laham, R.J. (2003). Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther. 10:285-291.
37. Gerber, H., Condorelli, F., Park, J., and Ferrara, N. (1997). Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. J. Biol. Chem. 272:23659-23667.
38. Ferrara, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29(Suppl 16):10-14.
39. Takeshita, S., Zheng, L.P., Brogi, E., Kearney, M., Pu, L.Q., Bunting, S., Ferrara, N., Symes, J.F., and Isner, J.M. (1994). Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J. Clin. Invest. 93:662-670.
40. Banai, S., Jaklitsch, M.T., Shou, M., Lazarous, D.F., Scheinowitz, M., Biro, S., Epstein, S.E., and Unger, E.F. (1993). Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183-2189.
41. Takeshita, S., Pu, L.-Q., Zheng, L.P., Ferrara, N., Stein, L.A., Sniderman, A.D., Isner, J.M., and Symes, J.F. (1994). Vascular endothelial growth factor induces dose-dependent revascularization in a rabbit model of persistent limb ischemia. Circulation 90 (Suppl II):228-234.
42. Isner, J.M., Walsh, K., Symes, J., Pieczek, A., Takeshita, S., Lowry, J., et al. (1995). Arterial gene therapy in patients with peripheral artery disease. Circulation 91:2687-2692.
43. Chelboun, J.O., Martins, R.N., Mitchell, C.A., and Chrilla, T.V. (1992). Basic FGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem. Biophys. Res. Comm. 185:510-516.
44. Baffour, R., Berman, J., Garb, J.L., Rhee, S.W., Kauffman, J., and Friedmann, P. (1992). Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose response effect of basic fibroblast growth factor. J. Vasc. Surg. 16:181-191.
45. Rissanen, T.T., Markkanen, J.E., Arve, K., Rutanen, J., Kettunen, M.I., Vajanto, I., et al. (2003). Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 17:100-102.
46. Houston, P., White, B.P., Campbell, C.J., and Braddock, M. (1999). Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. Hum. Gene Ther. 10:3031-3044.
47. Helisch, A., and Schaper, W. (2003). Arteriogenesis: the development and growth of collateral arteries. Microcirculation 10:83-97.
48. Voskuil, M., Van Royen, N., Hoefer, I.E., Seidler, R., Guth, B.D., Bode, C., et al. (2003). Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am. J. Physiol. Heart Circ. Physiol. 284(4): H1422-H1428.
49. van Royen, N., Hoefer, I., Buschmann, I., Kostin, S., Voskuil, M., Bode, C.H., et al. (2003). Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovasc. Res. 57:178-185.
50. Yanagisawa-Miwa, A., Uchida, Y., and Nakamura, F. (1992). Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257:1401-1403.
51. Lazarous, D.F., Scheinowitz, M., and Shou, M. (1995). Effects of chronic administration of basic fibroblast growth factor in collateral development in the canine heart. Circulation 91:145-153.
52. Heeschen, C., Weis, M., Aicher, A., Dimmeler, S., and Cooke, J.P. (2002). A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 110(4):527-536.
53. Roethy, W., Fiehn, E., Suehiro, K., Gu, A., Yi, G.H., Shimizu, J., et al. (2001). A growth factor mixture that significantly enhances angiogenesis in vivo. J. Pharmacol. Exp. Ther. 494-500.
54. Tsurumi, Y., Takeshita, S., Chen, D., Kearney, M., Rossow, S.T., Passeri, J., Horowitz, J.R., Symes, J.F., and Isner, J.M. (1996). Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94:3281-3290.
55. Nikol, S., Pelisek, J., Engelmann, M.G., Shimizu, M., Fuchs, A., Golda, A., et al. (2002). Vascular endothelial growth factor (VEGF 165) and its influence on angiogenesis versus arteriogenesis in different vascular beds. J. Endovasc. Ther. 9:842-845.
56. Kutryk, M.J. and Stewart, D.J. (2003). Angiogenesis of the heart. Microsc. Res. Tech. 60(2):138-158.
57. Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G.D., and Isner, J.M. (1998). Tei2 receptor ligands, angiopoietin-1 and angiopoietin-2 modulate VEGF-induced postnatal neovascularization. Circulation 83:233-240.
58. Shyu, K.-G., Manor, O., Magner, M., Yancopoulos, G.D., and Isner, J.M. (1998). Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in rabbit ischemic hindlimb. Circulation 98:2081-2087.
59. Van Bell, E., Witzenbichler, B., Chen, D., Silver, M., Chang, L., Schwall, R., and Isner, J.M. (1998). Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of VEGF. Circulation 97:381-390.
60. Vincent, K.A., Feron, O., and Kelly, R.A. (2002). Harnessing the response to tissue hypoxia. hIF-1alpha and therapeutic angiogenesis. Trends Cardiovasc. Med. 12:362-367.
61. Taniyama, Y., Morishita, R., Aoki, M., Nakagami, H., Yamamoto, K., Yamazaki, K., et al. (2001). Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 8:181-189.
62. Aoki, M., Morishita, R., Taniyama, Y., Kida, I., Moriguchi, A., Matsumoto, K., et al. (2000). Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther. 7:417-427.
63. Isner, J.M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., et al. (1996). Clinical evidence of angiogenesis after arterial gene transfer of phVEGF in patients with ischaemic limb. Lancet 348:370-374.
64. Lederman, R.J., Mendelsohn, F.O., Anderson, R.D., Saucedo, J.F., Tenaglia, A.N., et al. (2002). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359:2053-2058.
65. Schumacher, B., Pecher, P., von Specht, B.U., and Stegmann, T. (1998). Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation 97:645-650.
66. Hendel, R.C., Henry, T.D., Rocha-Singh, K., Isner, J.M., Kereiakes, D.J., Giordano, F.J., et al. (2000). Effect of intracoronary recombinant human vascular endotheliat growth factor on myocardial perfusion: Evidence for a dose-dependent effect. Circulation 101:118-121.
67. Henry, T.D., Rocha-Singh, K., Isner, J.M., Kereiakes, D.J., Giordano, F.J., Simons, M., et al. (2001). Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am. Heart J. 142:872-880.
68. Losordo, D.W., Vale, P.R., Hendel, R.C., Milliken, C.E., Fortuin, F.D., Cummings, N., et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105:2012-2018.
69. Merkle, C.J. and Montgomery, D.W.J. (2003). Gene therapy with vascular endothelial growth factor reduces angina. Cardiovasc. Nurs. 18:38-43.
70. Freedman, S.B., Vale, P., Kalka, C., Kearney, M., Pieczek, A., Symes, J., et al. (2002). Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum. Gene Ther. 13:1595-1603.
71. Vale, P.R., Losordo, D.W., Milliken, C.E., McDonald, M.C., Gravelin, L.M., et al. (2001). Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenes is using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103:2138-2143.
72. Losordo, D.W., Vale, P.R., Symes, J.F., Dunnington, C.H., Esakof, D.D., Maysky, M., et al. (1998). Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804.
73. Rosengart, T.K., Lee, L.Y., Patel, S.R., Kligfield, P.D., Okin, P.M., Hackett, N.R., et al. (1999). Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230:466-470.
74. Symes, J.F., Losordo, D.W., Vale, P.R., Lathi, K.G., Esakof, D.D., Mayskiy, M., et al. (1999). Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68:830-836.
75. Simons, M., Annex, B.H., Laham, R.J., Kleiman, N., Henry, T., Dauerman, H., et al. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105:788-793.
76. Henry, T.D., Annex, B., and Azrin, M. (2001). Double blind placebo controlled trial of recombinant human vascular endothelial growth factor, the VIVA Trial. J. Am. Col. Cardiol. 33:384(A).
77. Grines, C.L., Watkins, M.W., Helmer, G., Penny, W., Brinker, J., Marmur, J.D., et al. (2002). Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297.
78. Folkman, J. (1995). Clinical applications of research on angiogenesis. N. Engl. J. Med. 333:1757-1763.
79. Bussolino, F., Mantovani, A., and Perisico, G. (1997). Molecular mechanisms of blood vessel formation. Trends Biol. Sci. 22:251-256.
80. Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:389-395.
81. Waltenberger, J. (2001). Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res. 49(3):554-560.
82. Sim, E.K., Zhang, L., Shim, W.S., Lim, Y.L., and Ge, R. (2002). Therapeutic angiogenesis for coronary artery disease. J. Card. Surg. 17:350-354.
83. Lee, R.J., Springer, M.L., Blanco-Bose, W.E., Shaw, R., Ursell, P.C., and Blau, H.M. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102:898-901.
84. Dor, Y., Djonov, V., Abramovitch, R., Itin, A., Fishman, G.I., Carmeliet, P., et al. (2002). Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21:1939-1947.
85. Discher, D., Wasserlauf, B., Bishopric, N., and Webster, K.A. (2000). Conditional silencing as a means to suppress basal expression and augment the "therapeutic differential" of gene therapy vectors targeted to ischemic tissues. Circulation 102:No. 18.
86. Webster, K.A. (1999). Molecular switches for regulating therapeutic genes. Gene Ther. 6:951-954.
87. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967.
88. Hamano, K., Li, T.S., Kobayashi, T., Hirata K., Yano, M., Kohno, M., and Matsuzaki, M. (2002). Therapeutic angiogenesis induced by local autologous bone marrow cell implantation. Ann. Thorac. Surg. 73:1210-1215.
89. Kobayashi, T., Hamano, K., Li, T.S., Nishida, M., Ikenaga, S., Hirata, K., Zempo, N., and Esato, K. (2002). Angiogenesis induced by the injection of peripheral leukocytes and platelets. J. Surg. Res. 103:279-286.
90. Shintani, S., Murohara, T., Ikeda, H., Ueno, T., Sasaki, K., Duan, J., and Imaizumi, T. (2001). Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 103:897-903.
91. Clarke, D.L., Johansson, C.B., Wilbertz, J., Veress, B., Nilsson, E., Karlstrom, H., Lendahl, U., and Frisen, J. (2000). Generalized potential of adult neural stem cells. Science 288:1660-1663.
92. Hamano, K, Li, T.S., Kobayashi, T., Tanaka, N., Kobayashi, S., Matsuzaki, M., and Esato, K. (2001). The induction of angiogenesis by the implantation of autologous bone marrow cells: A novel and simple therapeutic method. Surgery 130:44-54.
93. Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., et al. (2002). Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 360:427-435.
94. Stamm, C., Westphal, B., Kleine, H.D., Petzsch, M., Kittner, C., Klinge, H., et al. (2003). Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361:45-46.
95. Ikenaga, S., Hamano, K., Nishida, M., Kobayashi, T., Li, T.S., Kobayashi, S., et al. (2001). Autologous bone marrow implantation induced angiogenesis and improved deteriorated exercise capacity in a rat ischemic hindlimb model. Surg. Res. 96:277-283.
96. Iba, O., Matsubara, H., Nozawa, Y., Fujiyama, S., Amano, K., Mori, Y., et al. (2002). Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 106:2019-2025.
97. Minamino, T., Toko, H., Tateno, K., Nagai, T., and Komuro, I. (2002). Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis? Lancet 360:2083-2084.
98. Kamihata, H., Hiroaki, M., Nishiue, T., Fujiyama, S., Tsutsumi, Y., Ozono, R., et al. (2001). Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands and cytokines. Circulation 104:1046-1052.
99. Kocher, A.A., Schuster, M.D., Szabolcs, M.J., Takuma, S., Burkhoff, J., Wang, S., et al. (2001). Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7(4):430-436.
100. Wang, J.S., Shum-Tim, D., Chedrawy, E., and Chiu, R.C.J. (2001). The coronary delivery of marrow stromal cells for myocardial regeneration: Pathophysiologic and therapeutic implications. J. Thorac. Cardiovasc. Surg. 122:699-705.
101. Orlic, D., Kajstura, J., Chimenti, S., Jaboniuk, I., Anderson, S.M., Li, B., et al. (2001). Bone marrow cells regenerate infarcted myocardium. Nature 410:701-705.
102. Orlic, D., Kajstura, J., Chimenti, S., Limana, F., Jaboniuk, I., Quaini, F., et al. (2001). Mobilized bone marrow cells repair the infarcted heart, improving function and survival. PNAS 98:10344-10349.
103. Tse, H.F., Kwong, Y.L., Chan, J.K., Lo, G., Ho, C.L., and Lau, C.P. (2003). Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361:47-49.
104. Yamashita, K., Kajstura, J., Discher, D.J., Wasserlauf, B.J., Bishopric, N.H., Anversa, P., and Webster, K.A. (2001). Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ. Res. 88:609-614.